Compare AU
Compare VISM vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard MSCI International Small Companies Index ETF (VISM) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VISM | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 270 | 77 |
Median incremental investment | $1,201.13 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,533.44 | $1,190.74 |
Average age group | 26 - 35 | > 35 |
Key Summary
VISM | CURE | |
|---|---|---|
Strategy | Vanguard MSCI International Small Companies Index ETF aims to track the returns and performance of the MSCI World ex-Australia Small Cap Index before considering fees, expenses, and tax. It tracks the performance of the index with dividends reinvested. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | Reliance Steel & Aluminum Co. (0.20 %) United Therapeutics Corp. (0.20 %) Axon Enterprise Inc. (0.19 %) | Natera Inc (2.77 %) Alnylam Pharmaceuticals Inc (2.60 %) Vertex Pharmaceuticals Inc (2.58 %) |
Top 3 industries | Industrials (19.35 %) Financials (14.55 %) Consumer Discretionary (12.64 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (62.44 %) Japan (12.99 %) United Kingdom of Great Britain and Northern Ireland (5.56 %) | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) |
Management fee | 0.32 % | 0.45 % |
Key Summary
VISM | CURE | |
|---|---|---|
Issuer | Vanguard | Global X |
Tracking index | MSCI World ex AU Small Cap | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.32 % | 0.45 % |
Price | $65.73 | $41.60 |
Size | N/A | $30.458 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 4.21 % | 4.24 % |
Market | ASX | ASX |
First listed date | 13/11/2018 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VISM | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 270 | 77 |
Median incremental investment | $1,201.13 | $640.11 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,533.44 | $1,190.74 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
VISM | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VISM | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |